AI-supported Target identification for Systemic Lupus Erythematosus.

Lupus is a multi-systemic autoimmune disease affecting approximately 1.5 million Americans and at least five million people worldwide. The majority of these cases, about 70%, are systemic lupus erythematosus (SLE) (1).

Written by
Dana Mavreli
  • Categories
  • Target Selection
Receive the latest newsletter directly to your inbox

Introduction

Genes/proteins involved in SLE pathophysiology

AI-supported Target identification for Systemic Lupus Erythematosus. image 0
Figure 1. Dendrogram view of proteins and genes associated with SLE (subset of total).
AI-supported Target identification for Systemic Lupus Erythematosus. image 0
Figure 2. Disease-target relationships with most evidence.

Emerging targets associated with SLE

AI-supported Target identification for Systemic Lupus Erythematosus. image 0
Figure 3. Identification of emerging targets using evidence score ranking.
AI-supported Target identification for Systemic Lupus Erythematosus. image 0
Figure 4. Exploring evidence by date of publication to discover the newest insights.

Target-centric analysis and druggability

AI-supported Target identification for Systemic Lupus Erythematosus. image 0
Figure 5. Implication of candidate targets identified previously in the pathogenesis of other autoimmune disorders.
AI-supported Target identification for Systemic Lupus Erythematosus. image 0
Figure 6. Understanding whether candidate targets identified are druggable.

Summary

References

Request access for your organisation

More on Target Selection